Brain metastases occur in approximately 15% of breast cancer patients and confer a dismal prognosis. Brain metastases are thought to increasing as a sanctuary site, as systemic control of breast cancer metastases improves. We are conducting microarray analysis of surgically resected brain metastases of breast cancer, using laser capture microdissection, amplification and 30K cDNA arrays. These data are being compared to a cohort of unmatched primary breast tumors, matched for histopathology, TNM and grade.A heat map comparing gene expression differences between brain metastses and unmatched primary tumors has been complied and is undergoing validation via RT-PCR. Targets of translational interest include overexpression of Her-2, Hexokinase 2, histone deacetylases. Phenotypic work is commencing using a labeled cell line of MDA-MB-231 which will metastasize to brain in vivo. HDAC inhibitor treatment of the line is under investigation.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010538-02
Application #
7061030
Study Section
(LP)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Ribot, Emeline J; Martinez-Santiesteban, Francisco M; Simedrea, Carmen et al. (2011) In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. J Magn Reson Imaging 34:231-8
Palmieri, Diane; Bronder, Julie L; Herring, Jeanne M et al. (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:4190-8
Palmieri, Diane; Chambers, Ann F; Felding-Habermann, Brunhilde et al. (2007) The biology of metastasis to a sanctuary site. Clin Cancer Res 13:1656-62
Steeg, Patricia S (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55-63